v3.26.1
Investments in associates - Summarised statement of comprehensive income (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Summarised statement of comprehensive income            
Revenue       $ 6,164 $ 5,810 $ 5,549
Attributable profit / (loss) for the year [1]       625 412 263
Total comprehensive income for the year [1]       797 335 246
Associates            
Summarised statement of comprehensive income            
Group share of gain / (loss)       4 (10) (30)
Bioventus, Inc.            
Summarised statement of comprehensive income            
Revenue       410 420 377
Attributable profit / (loss) for the year       8 (34) (152)
Group adjustments [2]       9 (2) 46
Total comprehensive income for the year       17 (36) (106)
Group share of gain / (loss)       $ 5 $ (10) $ (30)
Percentage of associate held 26.60% 27.13% 27.96%      
[1] Attributable to equity holders of the Company and wholly derived from continuing operations.
[2] Group adjustments include adjustments to align with Group policy.